RxDoctor Payments Data

Amit Bhargava, MD

Nephrology · Kissimmee, FLNPI 1699749440

Payments from drug & device makers

$2,189in general payments, 2019–2025

Across 64 payments — averaging $34.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$455
  • Amgen$305
  • Baxter Healthcare$264
  • Otsuka America Pharmaceutical, Inc.$224
  • Vantive US Healthcare LLC$169
  • Johnson & Johnson$100
  • plus $672 from 17 others

What the payments were for

  • Travel & lodging$45521%
  • Food & beverage$1,65376%
  • Education$814%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,189 in reported general payments places this provider in the 55th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$220,676
Medicare patients
418
Services billed
2,346

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tolvaptan21$52,415
JardianceEmpagliflozin37$38,004
FarxigaDapagliflozin Propanediol32$29,367
LokelmaSodium Zirconium Cyclosilicate25$26,528
ClinolipidFat Emulsion/Olive/Soy/Phospho21$4,905
RetacritEpoetin Alfa-Epbx12$4,563
ProsolParenteral Amino Acid 20% No.114$3,148
Calcitriol54$1,212
Torsemide85$1,191
Losartan Potassium80$477
Labetalol Hcl12$423
Potassium Chloride15$273
Spironolactone31$257
Metolazone20$243
Amlodipine Besylate31$204

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$59$55,89457 claims
Boehringer IngelheimJardiance$27$38,00437 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 756 nephrology providers in Florida.

Other nephrology in Kissimmee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →